Patents by Inventor James C. McRea
James C. McRea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8653139Abstract: The invention relates to drug substance preparations, pharmaceutical compositions and dosage forms containing (R)-(?)-2-(2-fluoro-4-biphenylyl) propionic acid as the active pharmaceutical ingredient, and limited amounts of specific product-related and process-related impurities.Type: GrantFiled: July 31, 2009Date of Patent: February 18, 2014Assignee: Aesica Pharmaceuticals LimitedInventors: Gaylen M. Zentner, James C. McRea, Mark S. Williams, Stephen J. Martin, Norman T. Smith, Catriona A. Oare
-
Publication number: 20110111025Abstract: The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient.Type: ApplicationFiled: April 30, 2010Publication date: May 12, 2011Applicant: Myriad Pharmaceuticals, Inc.Inventors: Gaylen M. Zentner, James C. McRea, Mark S. Williams, Gregory T. Oerhtman, Tracy Annette Powers
-
Publication number: 20100087538Abstract: The invention relates to drug substance preparations, pharmaceutical compositions and dosage forms containing (R)-(?)-2-(2-fluoro-4-biphenylyl) propionic acid as the active pharmaceutical ingredient, and limited amounts of specific product-related and process-related impurities.Type: ApplicationFiled: July 31, 2009Publication date: April 8, 2010Applicant: Myriad Pharmaceuticals, IncorporatedInventors: Gaylen M. Zentner, James C. McRea, Mark S. Williams, Stephen J. Martin, Norman T. Smith, Catriona A. Oare
-
Publication number: 20090069350Abstract: The present invention relates to pharmaceutical compositions and dosage compositions of compounds, including injectable formulations for the parenteral delivery of such compounds into patients in need of such treatment. Also featured are methods of making and using the compositions, including methods for the treatment of neoplastic diseases.Type: ApplicationFiled: November 17, 2008Publication date: March 12, 2009Applicant: Myriad Genetics, IncorporatedInventors: Gaylen M. Zentner, Chung Shih, James C. McRea
-
Patent number: 5858238Abstract: Methods and apparatuses for salvaging blood from a patient are disclosed. A blood salvaging and/or blood processing circuit coupled to a cardiopulmonary bypass circuit, cardiotomy circuit, or directly to the patient comprises a hemocentrator for removing water, fluids, and low molecular weight solutes by ultrafiltration and a sorbent-containing plasma separator for removing a selected solute, such as heparin. A combination device for salvaging blood comprises a closed plasma chamber containing a plasma chamber solution, a hollow fiber plasma-separating membrane for receiving blood and permitting plasma to be transported therethrough into the plasma chamber solution and for refiltering the treated plasma back into the blood circuit, a selective sorbent for contacting the selected solute in the plasma and binding the selected solute, and an ultrafiltration membrane for removing water, fluids, and low molecular weight components from the plasma.Type: GrantFiled: March 7, 1997Date of Patent: January 12, 1999Assignee: Baxter Research Medical, Inc.Inventors: James C. McRea, Stephanie Poulsen, Yong Nian Xia, Kirk Fowers
-
Patent number: 5416198Abstract: A polycationic system for the removal of polyanions from a fluid medium is formed by, first, activating a biocompatible hydroxylated support with an organic sulfonyl chloride, such as p-toluene-sulfonyl chloride, in the presence of a dialkylamino pyridine activation catalyst, such as 4-dimethylamino-pyridine (DMAP). The activated support is then reacted with a polymer having a polyamide backbone with pendent alkyl amine groups, such as poly-L-lysine (PLL), to form C--N bonds between an activated carbon from the hydroxylated polymer and an amine group from the polymeric polyamide. Finally, any unreacted activated sites on the hydroxylated polymer are capped or removed with an effective amount of capping agent such as a mercapto (--SH), hydroxy (--OH) or amino (--NH.sub.2) containing compound which reacts with the unreacted activated sites. The pendent alkyl amines on the polyamide backbone exist, at the appropriate pH, as polycations.Type: GrantFiled: February 5, 1993Date of Patent: May 16, 1995Assignee: Research Medical, Inc.Inventors: Christopher G. Anderson, James C. McRea
-
Patent number: 5324253Abstract: A system for selective removal of certain components from plasma drawn from a patient comprises an extracorporeal blood circulation circuit and a cannula. The extracorporeal blood circulation circuit has an uptake line for transporting blood from the patient, a plasma separator, and a return line connected to the plasma separator for transporting selectively depleted blood from the plasma separator to the patient. The plasma separator is connected to the uptake line for receiving the blood, selectively removing plasma components (e.g., heparin) by separating plasma from whole blood and interfacing such plasma with an adsorption substrate, recombining depleted plasma, and reinfusing selectively depleted blood into the return line for transport to the patient. The cannula has an uptake conduit with an intake end and an exit end, and a return conduit, connected to the uptake conduit, with an outflow end and an entry end.Type: GrantFiled: March 2, 1992Date of Patent: June 28, 1994Inventors: James C. McRea, Robert J. Todd
-
Patent number: 5226427Abstract: This invention relates to a stylet for use with a retrograde cardioplegia catheter and its methods of use. The stylet includes a stylet rod, a handle on the proximal end of the stylet rod and a predetermined curve in the distal end of the stylet rod. The handle has a thumb rest on the proximal end and a one or two finger loops extending outward from the handle. An obturator is located on the distal end of the predetermined curve to impede blood flow through a tip of the cardioplegia catheter during insertion of the catheter. The invention also contemplates methods for using the stylet.Type: GrantFiled: June 4, 1991Date of Patent: July 13, 1993Assignee: Research Medical Inc.Inventors: Gerald D. Buckberg, James C. McRea, Robert J. Todd
-
Patent number: 5211850Abstract: A system and method of achieving both convective and diffusive transport of plasma across a membrane accompanied by the selective removal of plasma components using sorbents followed by reinfusion of the purified plasma in a blood circulation system is achieved by pumping blood through a filter comprising a bundle of "U" shaped hollow fibers immersed in a closed plasma chamber containing sorbents in an electrolyte solution. As blood flows through the entry arm, due to positive transmembrane pressure difference, plasma filtration into the plasma chamber occurs. The entering plasma causes an increase in the chamber pressure but does not exceed the pressure in the entry arm. The increase in chamber pressure exceeds the pressure in the exit arm of filter where the transmembrane pressure difference is negative and the direction of filtration reverses causing reverse filtration/reinfusion of plasma from the chamber into the blood in the exit arm.Type: GrantFiled: July 26, 1991Date of Patent: May 18, 1993Assignee: Research Medical, Inc.Inventors: Udipi Shettigar, James C. McRea
-
Patent number: 4536572Abstract: Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides, p-(glutarylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-.alpha.-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins containing from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and show significant activity in depressing blood sugar levels.Type: GrantFiled: November 2, 1983Date of Patent: August 20, 1985Assignee: University of UtahInventors: Wan S. Kim, Seo Y. Jeong, James C. McRea
-
Patent number: 4489063Abstract: Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)- phenyl-.alpha.-D-gluco- and mannopyranosides, p-(glutarylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-.alpha.-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins containing from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and show significant activity in depressing blood sugar levels.Type: GrantFiled: February 6, 1984Date of Patent: December 18, 1984Inventors: Wan S. Kim, Seo Y. Jeong, James C. McRea
-
Patent number: 4489064Abstract: Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides, p-(glutarylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-.alpha.-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins containing from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and show significant activity in depressing blood sugar levels.Type: GrantFiled: February 6, 1984Date of Patent: December 18, 1984Inventors: Wan S. Kim, Seo Y. Jeong, James C. McRea
-
Patent number: 4483792Abstract: Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)- phenyl-.alpha.-D-gluco- and mannopyranosides, p-(glutarylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-.alpha.-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins containing from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and show significant activity in depressing blood sugar levels.Type: GrantFiled: December 20, 1983Date of Patent: November 20, 1984Inventors: Wan S. Kim, Seo Y. Jeong, James C. McRea
-
Patent number: 4478746Abstract: Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides, p-(glutarylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-.alpha.-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins containing from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and shown significant activity in depressing blood sugar levels.Type: GrantFiled: February 6, 1984Date of Patent: October 23, 1984Inventors: Wan S. Kim, Seo Y. Jeong, James C. McRea
-
Patent number: 4478830Abstract: Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides, p-(glutarylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-.alpha.-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins containing from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and show significant activity in depressing blood sugar levels.Type: GrantFiled: February 6, 1984Date of Patent: October 23, 1984Inventors: Wan S. Kim, Seo Y. Jeong, James C. McRea
-
Patent number: 4444683Abstract: Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides, p-(glutarylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-.alpha.-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins containing from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and show significant activity in depressing blood sugar levels.Type: GrantFiled: November 17, 1982Date of Patent: April 24, 1984Assignee: University of UtahInventors: Wan S. Kim, Seo Y. Jeong, James C. McRea